Carcinoma of the cervix, FIGO Stage IB

Treatment failures

Leon L. Adcock, Roger A. Potish, Thomas M. Julian, Takashi Okagaki, Konald A. Prem, Leo B. Twiggs, John E. Savage

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

All patients with carcinoma of the cervix, FIGO Stage IB, treated at the University of Minnesota Hospitals during a 10-year period were reviewed. Of the 220 patients 31 (14.0%) developed recurrent disease and did not survive. Thirteen patients had pelvic wall recurrences, with concurrent cervical involvement. No patient had a resectable pelvic recurrence. Hysterectomy was subsequently performed on 10 of the 172 patients who received radiation therapy. Carcinoma was not present in any of the operative specimens although two patients with adenocarcinoma later died of metastatic cancer. Median time of recurrence was 9 months, with median survival following recurrence of 6 months. Cervical cytology was not of value in the early diagnosis of recurrent disease. The 5-year adjusted actuarial survival rate for patients with adenosquamous carcinoma was significantly lower than that for patients with squamous cell carcinoma. The median age of patients not surviving with adenosquamous carcinoma was significantly lower than that for patients not surviving with squamous cell carcinoma. Patients with invasive carcinoma presumably confined to the cervix may have disseminated disease. It is essential such selected patients receive primary treatment that includes systemic therapy.

Original languageEnglish
Pages (from-to)218-225
Number of pages8
JournalGynecologic Oncology
Volume18
Issue number2
DOIs
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Treatment Failure
Cervix Uteri
Carcinoma
Adenosquamous Carcinoma
Recurrence
Squamous Cell Carcinoma
Hysterectomy
Cell Biology
Early Diagnosis
Adenocarcinoma
Radiotherapy
Survival Rate

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Adcock, L. L., Potish, R. A., Julian, T. M., Okagaki, T., Prem, K. A., Twiggs, L. B., & Savage, J. E. (1984). Carcinoma of the cervix, FIGO Stage IB: Treatment failures. Gynecologic Oncology, 18(2), 218-225. https://doi.org/10.1016/0090-8258(84)90029-5

Carcinoma of the cervix, FIGO Stage IB : Treatment failures. / Adcock, Leon L.; Potish, Roger A.; Julian, Thomas M.; Okagaki, Takashi; Prem, Konald A.; Twiggs, Leo B.; Savage, John E.

In: Gynecologic Oncology, Vol. 18, No. 2, 01.01.1984, p. 218-225.

Research output: Contribution to journalArticle

Adcock, LL, Potish, RA, Julian, TM, Okagaki, T, Prem, KA, Twiggs, LB & Savage, JE 1984, 'Carcinoma of the cervix, FIGO Stage IB: Treatment failures', Gynecologic Oncology, vol. 18, no. 2, pp. 218-225. https://doi.org/10.1016/0090-8258(84)90029-5
Adcock LL, Potish RA, Julian TM, Okagaki T, Prem KA, Twiggs LB et al. Carcinoma of the cervix, FIGO Stage IB: Treatment failures. Gynecologic Oncology. 1984 Jan 1;18(2):218-225. https://doi.org/10.1016/0090-8258(84)90029-5
Adcock, Leon L. ; Potish, Roger A. ; Julian, Thomas M. ; Okagaki, Takashi ; Prem, Konald A. ; Twiggs, Leo B. ; Savage, John E. / Carcinoma of the cervix, FIGO Stage IB : Treatment failures. In: Gynecologic Oncology. 1984 ; Vol. 18, No. 2. pp. 218-225.
@article{70dbef7a7ba54dd48f52d0a30bf97b51,
title = "Carcinoma of the cervix, FIGO Stage IB: Treatment failures",
abstract = "All patients with carcinoma of the cervix, FIGO Stage IB, treated at the University of Minnesota Hospitals during a 10-year period were reviewed. Of the 220 patients 31 (14.0{\%}) developed recurrent disease and did not survive. Thirteen patients had pelvic wall recurrences, with concurrent cervical involvement. No patient had a resectable pelvic recurrence. Hysterectomy was subsequently performed on 10 of the 172 patients who received radiation therapy. Carcinoma was not present in any of the operative specimens although two patients with adenocarcinoma later died of metastatic cancer. Median time of recurrence was 9 months, with median survival following recurrence of 6 months. Cervical cytology was not of value in the early diagnosis of recurrent disease. The 5-year adjusted actuarial survival rate for patients with adenosquamous carcinoma was significantly lower than that for patients with squamous cell carcinoma. The median age of patients not surviving with adenosquamous carcinoma was significantly lower than that for patients not surviving with squamous cell carcinoma. Patients with invasive carcinoma presumably confined to the cervix may have disseminated disease. It is essential such selected patients receive primary treatment that includes systemic therapy.",
author = "Adcock, {Leon L.} and Potish, {Roger A.} and Julian, {Thomas M.} and Takashi Okagaki and Prem, {Konald A.} and Twiggs, {Leo B.} and Savage, {John E.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0090-8258(84)90029-5",
language = "English",
volume = "18",
pages = "218--225",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Carcinoma of the cervix, FIGO Stage IB

T2 - Treatment failures

AU - Adcock, Leon L.

AU - Potish, Roger A.

AU - Julian, Thomas M.

AU - Okagaki, Takashi

AU - Prem, Konald A.

AU - Twiggs, Leo B.

AU - Savage, John E.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - All patients with carcinoma of the cervix, FIGO Stage IB, treated at the University of Minnesota Hospitals during a 10-year period were reviewed. Of the 220 patients 31 (14.0%) developed recurrent disease and did not survive. Thirteen patients had pelvic wall recurrences, with concurrent cervical involvement. No patient had a resectable pelvic recurrence. Hysterectomy was subsequently performed on 10 of the 172 patients who received radiation therapy. Carcinoma was not present in any of the operative specimens although two patients with adenocarcinoma later died of metastatic cancer. Median time of recurrence was 9 months, with median survival following recurrence of 6 months. Cervical cytology was not of value in the early diagnosis of recurrent disease. The 5-year adjusted actuarial survival rate for patients with adenosquamous carcinoma was significantly lower than that for patients with squamous cell carcinoma. The median age of patients not surviving with adenosquamous carcinoma was significantly lower than that for patients not surviving with squamous cell carcinoma. Patients with invasive carcinoma presumably confined to the cervix may have disseminated disease. It is essential such selected patients receive primary treatment that includes systemic therapy.

AB - All patients with carcinoma of the cervix, FIGO Stage IB, treated at the University of Minnesota Hospitals during a 10-year period were reviewed. Of the 220 patients 31 (14.0%) developed recurrent disease and did not survive. Thirteen patients had pelvic wall recurrences, with concurrent cervical involvement. No patient had a resectable pelvic recurrence. Hysterectomy was subsequently performed on 10 of the 172 patients who received radiation therapy. Carcinoma was not present in any of the operative specimens although two patients with adenocarcinoma later died of metastatic cancer. Median time of recurrence was 9 months, with median survival following recurrence of 6 months. Cervical cytology was not of value in the early diagnosis of recurrent disease. The 5-year adjusted actuarial survival rate for patients with adenosquamous carcinoma was significantly lower than that for patients with squamous cell carcinoma. The median age of patients not surviving with adenosquamous carcinoma was significantly lower than that for patients not surviving with squamous cell carcinoma. Patients with invasive carcinoma presumably confined to the cervix may have disseminated disease. It is essential such selected patients receive primary treatment that includes systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021174009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021174009&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(84)90029-5

DO - 10.1016/0090-8258(84)90029-5

M3 - Article

VL - 18

SP - 218

EP - 225

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -